FDA.reportPublic FDA data

belantamab mafodotin-blmf 70 MG Injection [Blenrep]

RxCUI
2725587
RxNorm name
belantamab mafodotin-blmf 70 MG Injection [Blenrep]
Display name
belantamab mafodotin-blmf 70 MG Injection [Blenrep]
Full name
belantamab mafodotin-blmf 70 MG Injection [Blenrep]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:16

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761440Blenrepbelantamab mafodotin-blmf351(a)Rx2026-10-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
aef7c34c-fef8-407c-99c0-a68aded53c60BLENREP 70 MG Injection [PSN] · belantamab mafodotin-blmf 70 MG Injection [Blenrep] [SBD] · Blenrep 70 MG Injection [SY]31These highlights do not include all the information needed to use BLENREP safely and effectively. See full prescribing information for BLENREP. BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use Initial U.S. Approval: 202020251023